LYEL
HealthcareLyell Immunopharma, Inc.
$21.26-3.52 (-14.19%)
Prev Close
$24.77
Open
$24.78
High
$25.48
Low
$21.02
Volume
103.1K
Market Cap
$542.1M
P/E
—
Div Yield
—
LYEL Price Chart
LYEL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026↗ | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M | 1,426,530 |
| Mar 9, 2026↗ | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M | 1,426,530 |
| Feb 12, 2026↗ | Hill Stephen J. | officer: Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 17,795 |
| Feb 12, 2026↗ | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 16,938 |
| Feb 12, 2026↗ | Seely Lynn | director, officer: President and CEO | Sell | 7,455 | $23.39 | $174.4K | 74,266 |
| Feb 11, 2026↗ | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 15,637 |
| Feb 11, 2026↗ | Hill Stephen J. | officer: Chief Operating Officer | Sell | 1,345 | $23.37 | $31.4K | 19,031 |
| Feb 11, 2026↗ | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,818 | $23.37 | $42.5K | 18,609 |
| Feb 11, 2026↗ | Seely Lynn | President and CEO | Sell | 7,893 | $23.38 | $184.5K | 81,721 |
| Feb 10, 2026↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026↗ | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026↗ | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026↗ | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Jan 6, 2026↗ | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 8,077 |
| Dec 24, 2025↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025↗ | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025↗ | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025↗ | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025↗ | Newton Charles W. | Chief Financial Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025↗ | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
| Mar 31, 2025↗ | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025↗ | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K | 0 |
| Mar 17, 2025↗ | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K | 0 |
| Mar 14, 2025↗ | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K | 0 |
| Mar 14, 2025↗ | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K | 0 |
LYEL Insider Buying Activity
The following table shows recent insider purchases of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026↗ | ARCH Venture Fund XIII, L.P. | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M | 1,426,530 |
| Mar 9, 2026↗ | ARCH Venture Partners IX, LLC | 10 percent owner | Buy | 488,090 | $25.61 | $12.50M | 1,426,530 |
| Mar 31, 2025↗ | BRAWLEY OTIS W | Director | Buy | 35,640 | $0.56 | $20.0K | 0 |
| Mar 21, 2025↗ | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115.2K | 0 |
| Mar 17, 2025↗ | Newton Charles W. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111.6K | 0 |
| Mar 14, 2025↗ | Klausner Richard | Director | Buy | 158,000 | $0.60 | $94.9K | 0 |
| Mar 14, 2025↗ | Seely Lynn | President and CEO | Buy | 175,000 | $0.61 | $106.2K | 0 |
LYEL Insider Selling Activity
The following table shows recent insider sales of Lyell Immunopharma, Inc. (LYEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026↗ | Hill Stephen J. | officer: Chief Operating Officer | Sell | 1,236 | $23.39 | $28.9K | 17,795 |
| Feb 12, 2026↗ | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,671 | $23.39 | $39.1K | 16,938 |
| Feb 12, 2026↗ | Seely Lynn | director, officer: President and CEO | Sell | 7,455 | $23.39 | $174.4K | 74,266 |
| Feb 11, 2026↗ | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 15,637 |
| Feb 11, 2026↗ | Hill Stephen J. | officer: Chief Operating Officer | Sell | 1,345 | $23.37 | $31.4K | 19,031 |
| Feb 11, 2026↗ | Lee Gary K. | officer: Chief Scientific Officer | Sell | 1,818 | $23.37 | $42.5K | 18,609 |
| Feb 11, 2026↗ | Seely Lynn | President and CEO | Sell | 7,893 | $23.38 | $184.5K | 81,721 |
| Feb 10, 2026↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $5.9K | 0 |
| Feb 9, 2026↗ | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $2.5K | 0 |
| Feb 9, 2026↗ | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3.4K | 0 |
| Feb 9, 2026↗ | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10.1K | 0 |
| Jan 6, 2026↗ | Bulis Veronica Sanchez | officer: VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 8,077 |
| Dec 24, 2025↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 2,072 | $35.80 | $74.2K | 0 |
| Nov 10, 2025↗ | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $3.8K | 0 |
| Nov 10, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $1.5K | 0 |
| Nov 10, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2.2K | 0 |
| Nov 10, 2025↗ | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $6.6K | 0 |
| Aug 20, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 1,004 | $10.54 | $10.6K | 0 |
| Aug 20, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025↗ | Newton Charles W. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15.3K | 0 |
| Aug 20, 2025↗ | Seely Lynn | President and CEO | Sell | 7,257 | $10.54 | $76.5K | 0 |
| Aug 11, 2025↗ | Hill Stephen J. | Chief Operating Officer | Sell | 185 | $10.43 | $1.9K | 0 |
| Aug 11, 2025↗ | Lee Gary K. | Chief Scientific Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025↗ | Newton Charles W. | Chief Financial Officer | Sell | 267 | $10.43 | $2.8K | 0 |
| Aug 11, 2025↗ | Seely Lynn | President and CEO | Sell | 797 | $10.43 | $8.3K | 0 |
LYEL Insiders
Similar Stocks to LYEL
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$538.00+0.97%
$21.50B
INCY
Incyte Corporation
$92.25+0.27%
$20.10B
RVMD
Revolution Medicines, Inc.
$95.44+0.39%
$20.10B
MRNA
Moderna, Inc.
$52.38-1.89%
$19.96B